Is there a link between the circulating renin-angiotensin system and coronary disease? A sceptical view

J D Swales

Research on the renin-angiotensin system during the 20th century provides a history of the impact of scientific growth upon our understanding of pathophysiology. The techniques of experimental physiology, “classical” chemistry, biochemistry, and pathology have had a major impact which has been succeeded by the newer techniques of immunochemistry and molecular biology. Epidemiology and clinical trials methodology have also played critical roles. Patient wellbeing has been significantly advanced, initially by the development of diagnostic tests based upon this technology and latterly by the development of potent drugs which inhibit the renin-angiotensin system. In many ways it is remarkable that the relationship between the renin-angiotensin system and the most common cause of cardiovascular morbidity and mortality (that is, ischaemic heart disease) is still uncertain and controversial. It now cannot be denied that the renin-angiotensin system plays a significant role in cardiovascular disease. What remains uncertain is the mechanism and extent of the association, and to what extent the system has an impact upon cardiac disease independent of its well defined effects upon blood pressure. The purpose of this review is to make clear my grounds for scepticism about the current evidence.

Types of evidence

Associations such as those described between plasma renin activity and coronary heart disease could be the result of pathological effects of high circulating (or perhaps locally generated) angiotensin II concentrations. There are, however, two alternative explanations that cannot be excluded in such largely retrospective reports. High plasma renin activity could be a result of pre-existing vascular damage or the association could be due to unrecognised confounding factors which influence both plasma renin activity and the incidence of ischaemic heart disease. The demonstration of causality demands three types of evidence.

Biologically plausible mechanisms

It has long been known that under certain circumstances renin can have deleterious effects upon both the myocardium and vascular tissue. Thus, Asscher and Anson showed that renal extracts produced vascular lesions and effusions which they attributed to a vascular permeability factor. It was subsequently found that angiotensin II infusions mimicked this effect. The specificity of the effect was, however, challenged by the observation that preventing the rise in blood pressure produced by angiotensin II also inhibited the increase in vascular permeability, suggesting that the effect was a mechanical one. Mohring and his colleagues challenged this explanation, and in an intriguing group of studies in Goldblatt two-kidney-one-clp hypertension in the rat, they showed that high plasma renin activity concentrations were associated with weight loss and death, while reduction in plasma renin with saline infusion resulted in a remarkable improvement in clinical state and survival. They were, however, unable to discriminate between an adverse effect of sodium and water depletion and increased plasma renin concentrations. It is also noteworthy that two rat models of induced hypertension often accompanied by severe vascular lesions—Goldblatt one-kidney-one-clp and deoxycorticosterone-salt hypertension—are associated with low renin concentrations. Direct effects of angiotensin II on the myocardium were demonstrated by Kremer et al who produced extensive focal myocardial necrosis by infusing angiotensin II into rabbits. These lesions were, however, only seen with high angiotensin II concentrations and were probably related to catecholamine

Glossary of trials

HAPPHY—Heart attack primary prevention in hypertension
IPPPSH—International prospective primary prevention study in hypertension
MAPHY—Metoprolol atherosclerosis prevention in hypertensives study
SHEP—Systolic hypertension in the elderly programme
induced damage which can produce similar appearances in patients with pheochromocytoma. The lesions are quite distinct from those produced by ischaemic heart disease and therefore probably do not support the theory that there is a link between the renin-angiotensin system and ischaemic heart disease.

The development of inhibitors of the renin-angiotensin system yielded more direct evidence. In experimental preparations, angiotensin converting enzyme (ACE) inhibitors were shown to increase coronary blood flow4 and to prevent remodelling following experimental myocardial infarction. The latter was associated with prolongation of survival. Although ACE inhibitors improve coronary blood flow in normal subjects,10 it has been more difficult to demonstrate improvement in coronary blood flow using ACE inhibitors in patients with established coronary heart disease. Such studies do not support the relation between renin and the incidence of coronary events. Further, they do not discriminate between specific direct effects of angiotensin II upon the heart, effects of ACE inhibitors due to other mechanisms such as bradykinin potentiation, or effects of ACE inhibitors due to particularly favourable haemodynamic effects.

Molecular biological techniques have demonstrated persuasively that angiotensin II induces expression of a wide range of genes in vascular tissue. Some of these genes are implicated in atherogenesis and probably mediate the growth effects produced by angiotensin II in vascular smooth muscle cells in tissue culture. (The difficulty in extrapolating such observations to the in vivo situation is that angiotensin II may simultaneously stimulate both proliferative pathways (oncogene expression) and antiproliferative pathways (for example, PDGF-AA and TGF-β).) This may explain the observation that in some situations only hypertrophy is produced in vivo, while changing tissue culture media composition may give rise to angiotensin II induced hyperplasia in vitro. In vivo experiments also suggest that angiotensin II can, under some circumstances, have a trophic effect independent of blood pressure. Thus, ACE inhibitors prevented or attenuated the development of myointimal hyperplasia after endothelium denudation in the rat carotid artery. This effect may, however, be due to bradykinin potentiation rather than ACE inhibition. Griffin et al showed that resistance vessel hypertrophy induced by angiotensin II was not prevented when the rise in blood pressure was inhibited by the use of hydralazine. However, the haemodynamic effects of hydralazine on pulse pressure may have had an important effect on resistance vessel growth. Harrap et al demonstrated persuasively that the regression in resistance vessel hypertrophy produced by ACE inhibitors was completely inhibited when their blood pressure lowering effect was prevented with saline infusion, although in this case, of course, angiotensin II levels remained suppressed or may have been further reduced. While in some studies ACE inhibitors have been shown to reduce experimental atheroma,16 such effects have not been carefully distinguished from the haemodynamic effect of these agents. The effects are not observed, for example, with other angiotensin II lowering antihypertensive treatment such as β blockade.17

Angiotensin II may play a role in vascular injury mediated by other cytokines. Recently, it has been shown that it increases vascular permeability factor mRNA gene expression in human vascular tissue. It has been associated with increased vascular permeability in diabetes although no direct association with coronary heart disease has yet been shown. Whether this mechanism explains the earlier observations of increased vascular permeability independent of blood pressure changes remains to be seen, but potentially this mechanism is extremely important, although its relevance to ischaemic heart disease is uncertain.

In summary, angiotensin II can in some experimental settings be shown to have a plethora of actions upon vascular tissue. How far these can be related to in vivo mechanisms in man is uncertain until more clinical and experimental studies are conducted.

Evidence from association studies
The first evidence that plasma renin was associated with cardiovascular disease came from Laragh's group in New York. Since plasma renin is influenced by sodium intake, they used a nomogram in which plasma renin was plotted against 24 hour sodium excretion in order to increase the sensitivity of the analysis to abnormalities. When a clinic population of 219 patients was examined using the renin profile, it was reported that over a 10 year period none of the 59 patients classified as "low renin hypertension" suffered a heart attack or stroke, whereas 14% of the 124 patients in the normal plasma renin group and 14% of the 36 patients in the high plasma renin group had suffered one or the other. In a subsequent report based upon 640 patients, the relative protection against heart attack was again observed in the low renin group, but on this occasion strokes were equally distributed.19

This type of association study, based upon a referred clinic population, is notoriously subject to systematic error. The renin subgroups were not matched for age, blood pressure, or ethnic origin. The possibility of differential treatment effects in the three groups was not considered. Subsequent clinic based studies yielded divergent results,20 22 and the prognostic value of "renin profiling" has not been generally accepted.17 Even if plasma renin values were useful prognostically, this would not necessarily provide support for the view that plasma renin was vasculotoxic. Thus high renin levels could reflect increased sympathetic activity, which itself may be associated with impaired prognosis. Alternatively, increased renin could result from hypertensive vascular damage to the afferent arteriole. Renin levels are usually elevated in malignant
hypertension which would carry a much worse prognosis. 24

Despite these criticisms, a prospective study partially supports the original observations. Alderman et al carried out renin sodium profiling on 1717 hypertensive subjects identified by worksite screening. 25 Subjects were followed for a mean of 8-3 years. The incidence of myocardial infarction per 1000 person-years was 14-7 in high renin hypertensive subjects, 5-6 in normal renin hypertensive subjects, and 2-8 in low renin hypertensive patients. The risk ratio for high versus low renin hypertension was 5-3 (confidence intervals 3-4 to 8-3). Mortality rates showed a similar gradient. A systematic search was carried out for such confounding factors as race, sex, age at entry, serum cholesterol, smoking status, left ventricular hypertrophy, blood glucose, body mass index, history of cardiovascular disease, blood pressure, and use of β blockers, all with negative results. There was no relation between renin profile and the incidence of stroke.

The results from this impressive cohort study (n = 1717) are in marked contrast to that of Whitehead et al.26 The previous study involved a younger cohort and included only 126 myocardial infarction cases from 1512 subjects in a single centre. The failure to demonstrate a relation between renin profile and subsequent stroke suggests that the relation observed in the earlier study was due to an unrecognised confounder.

The only study of similar design from a United Kingdom population does not support the work of Alderman et al.26 Meade et al analysed plasma renin activity in a mixed group of hypertensive and normotensive subjects (1999 in total). Twenty-four gave a history of previous myocardial infarction and were found to have a lower plasma renin activity than subjects without such a history. This study did not use renin sodium profiling, included a majority of normotensive subjects, and did not examine potential mismatching of renin subgroups for other cardiovascular risk factors: this is particularly important as low renin subjects are likely to be older. A later follow-up study by the same group examined outcome in 803 men.27 Most were normotensive and only 242 were diagnosed as hypertensive. Eighty six first coronary events were observed and there was no relation with plasma renin activity in the group as a whole. There was a weak trend towards increased coronary events in the third of the hypertensive population with highest plasma renin (risk ratio of 1-26, confidence interval 0-63 to 2-56).

The populations investigated are clearly different in these two studies. In both, the number of events was limited and the power to detect genuine associations was correspondingly low. Despite this, the British study was powerful enough to detect significant effects of cholesterol, body mass index, and systolic blood pressure on the incidence of myocardial infarction. It seems likely, therefore, that if plasma renin has prognostic value, this is at best confined to hypertensive subjects.

One other prospective study by Alderman et al bears upon this issue.28 The group conducted a study in which 2937 hypertensive subjects were followed for an average of 3-8 years. In a Cox multivariate analysis, log plasma renin activity together with age, systolic blood pressure, and cholesterol was directly associated with the incidence of myocardial infarction, whereas urinary sodium was inversely associated with incidence of myocardial infarction (that is, higher sodium intakes appeared to carry a protective effect). Interestingly, when plasma renin activity was excluded from the multiple regression model, the sodium-myocardial infarction association became substantially stronger. On the other hand, when plasma renin activity as well as sodium were included, both associations remained significant, indicating that the relation of the two with myocardial infarction was partially independent. The presence of apparent associations when renin sodium profiling is used, together with these observations, suggest that high plasma renin activity is not acting as an indicator of suboptimal sodium intake.

In conclusion, these association studies do not provide consistent evidence for a renin-coronary heart disease relation. Even where it has been shown, the possibility remains that it is attributable to unrecognised confounding factors, and the failure of treatment to eliminate a putative relationship at recruitment to these studies remains puzzling.

**Intervention trials**

The gold standard design for demonstrating a causal role for circulating renin in coronary heart disease would be an intervention trial in which specific inhibition of the renin-angiotensin system protected susceptible patients against ischaemic heart disease. Such studies are not available. There are, however, several trials which do indirectly shed light upon this hypothesis. There are three types: (1) studies in which the incidence of coronary heart disease has been examined when blood pressure is lowered by manoeuvres which either stimulate or reduce plasma renin levels; (2) studies in which the impact of more specific inhibition of the renin-angiotensin system has been examined in heart failure patients who are at high risk of recurrent myocardial infarction; and (3) comparative trials using vascular remodelling as a surrogate end point for coronary heart disease.

**INTERVENTION TRIALS IN HYPERTENSION**

In some trials which have examined the impact of antihypertensive treatment on cardiovascular endpoints, treatments which stimulate and reduce circulating renin have been used. In the Medical Research Council (MRC) trial in mild hypertension, patients...
were randomly allocated to bendrofluazide, propranolol, or placebo. The results were
difficult to analyse because second line treatment with enalapril was also
randomly allocated in a subgroup of patients. However, the high doses of bendrofluazide
used (10 mg/d) would be expected to raise plasma renin while propranolol would be
expected to reduce it. Strokes were significantly more frequent in the bendrofluazide
group, but the absolute numbers are small (17 beside 10). GFR was significantly
lower in the bendrofluazide group, but this finding was also more widely
reported in the placebo group (54 versus 52 ml/min per 1.73 m2). Coronary events were not
significantly reduced in either group (5.6 per 1000 person-years on bendrofluazide, 4.8 on
propranolol, and 5.4 on placebo). Neither of these findings, therefore, supports the hypothe-
sis that induced changes in plasma renin influence the incidence of stroke or heart attack
independently of changes in blood pressure. Only if total infarction rates (that is, silent plus
clinical infarctions) are taken into account did the propranolol group fare significantly better
when compared with the bendrofluazide treated group. In the MRC trial of treatment
in older adults, patients were randomised to atenolol or a hydrochlorothiazide-amiloride
combination. The diuretic group showed signi-
ificantly reduced risks of stroke (31%), coro-
nary events (44%), and all cardiovascular events (35%) compared with placebo. There
were no significant reductions in the incidence of any of these three primary end points in the
β blocker group; the difference between diuretic and β blocker groups was statistically
significant in each case.

Two other trials have attempted to detect preferential effects of β blockers on coronary
events in the treatment of hypertension: the HAPPHY and IPPSHI trials. Neither
detected any significant reduction in coronary heart disease in the β blocker treated group,
although this therapy would have been expected to lower renin levels. In both cases,
however, additional drug treatment may have complicated the issue. Only when the HAP-
PHY trial was extended as the MAPHY trial was there a significantly lower mortality from
myocardial infarction in the metoprolol treated group compared with those who received diuretics. β Blockade clearly has an impact on cardiac disease quite distinct from
any putative effect of renin lowering, and the interpretation of these results in the present
case is therefore debatable. However, it seems clear that in some patient groups (par-
ticularly the elderly), treatment which raises renin concentrations has a major impact upon
coronary heart disease of the approximate order of the epidemiological risk. The 27% reduction
in myocardial infarction in the SHEP trial, which used chlorthalidone as first line treatment, is consistent with this.

Trials in congestive cardiac failure
ACE inhibitors have been shown to improve both morbidity and mortality in patients with
left ventricular dysfunction. In some of these trials there has been an unexpected but
significant reduction in recurrent myocardial infarction. In one large trial, however, no
reduction was observed. How far favourable effects are attributable to a specific effect upon
circulating angiotensin II and how far they are attributable to a particularly favourable
haemodynamic effect is uncertain, and find-
ings in this very special situation cannot rea-
sonably be extrapolated to primary prevention studies.

Effect of ACE inhibitors on vascular remodelling
Hypertension is associated with an increased
call to lumen ratio in the resistance vessel. This is mainly or wholly due to rearrangement
of the media resulting in a reduction of luminal diameter without any increase in mass.
The mechanism of this effect is unknown. Two studies have compared ACE inhibition with β blockade and both have found that
chronic treatment with ACE inhibitors reverses vascular remodelling in subcutaneous
resistance vessels. Although some data are not
Although this has been attributed to specific effects of angiotensin II upon the vasculature,
this interpretation is not particularly persua-
sive, as β blockade would also be associated with some reduction in angiotensin II,
although probably not to the same extent as ACE inhibitors. In addition, vascular remodel-
ling represents a fundamentally different pathological process from coronary atheroma,
and the relevance of these findings is doubtful; however, if coronary vessels underwent similar
remodelling, potential effects on coronary flow
reserve might be of importance.

Conclusion
There is no consistent body of evidence to
implicate circulating renin independently of
blood pressure in the pathogenesis of coronary
events (table). Although some data are
impressive, they are all controversial, with
divergence both in epidemiology and trial
results. Likewise, biological events triggered
by angiotensin II are complex and opposing
processes are stimulated in vitro, making in
vivo prediction impossible. The development of
more specific inhibitors of the renin-

<table>
<thead>
<tr>
<th>Evidence implicating renin in pathogenesis of coronary events</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Evidence</strong></td>
</tr>
<tr>
<td>Biological processes</td>
</tr>
<tr>
<td>Association studies</td>
</tr>
<tr>
<td>Intervention studies</td>
</tr>
</tbody>
</table>

**Trials in congestive cardiac failure**
ACE inhibitors have been shown to improve both morbidity and mortality in patients with
left ventricular dysfunction. In some of these trials there has been an unexpected but
significant reduction in recurrent myocardial infarction. In one large trial, however, no
reduction was observed. How far favourable effects are attributable to a specific effect upon
circulating angiotensin II and how far they are attributable to a particularly favourable
haemodynamic effect is uncertain, and find-
ings in this very special situation cannot rea-
sonably be extrapolated to primary prevention studies.

**Effect of ACE inhibitors on vascular remodelling**
Hypertension is associated with an increased
call to lumen ratio in the resistance vessel. This is mainly or wholly due to rearrangement
of the media resulting in a reduction of luminal diameter without any increase in mass.
The mechanism of this effect is unknown. Two studies have compared ACE inhibition with β blockade and both have found that
chronic treatment with ACE inhibitors reverses vascular remodelling in subcutaneous
resistance vessels. Although some data are not
Although this has been attributed to specific effects of angiotensin II upon the vasculature,
this interpretation is not particularly persua-
sive, as β blockade would also be associated with some reduction in angiotensin II,
although probably not to the same extent as ACE inhibitors. In addition, vascular remodel-
ling represents a fundamentally different pathological process from coronary atheroma,
and the relevance of these findings is doubtful; however, if coronary vessels underwent similar
remodelling, potential effects on coronary flow
reserve might be of importance.
angiotensin system may make the hypothesis easier to test, although the need for end point trials makes such investigation complex and expensive. At present there is insufficient persuasive evidence to render this hypothesis relevant in treating individual patients.


